P. J. Loehrer

768 total citations
18 papers, 603 citations indexed

About

P. J. Loehrer is a scholar working on Oncology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P. J. Loehrer has authored 18 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Neurology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P. J. Loehrer's work include Cancer Treatment and Pharmacology (7 papers), Myasthenia Gravis and Thymoma (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). P. J. Loehrer is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Myasthenia Gravis and Thymoma (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). P. J. Loehrer collaborates with scholars based in United States. P. J. Loehrer's co-authors include Stephen D. Williams, Lawrence Einhorn, C R Nichols, Matthew Burns, Anupama Kurup, Rajesh Ramanathan, Mark Powell, Christopher H. Crane, Joanna M. Brell and William Pao and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and European Journal of Cancer.

In The Last Decade

P. J. Loehrer

18 papers receiving 596 citations

Peers

P. J. Loehrer

NEURO

ONCOL

SURGE

EDM

EPIDE

Ryunosuke Machida Japan

Moshe Friedman United States

Paola Coco Italy

Paolo Montemaggi Italy

Giancarlo Montini Italy

Yirui Zhai China

Bonnie J. Trochanowski United States

Ellen Chase United States

Kvols Lk United States

Golbey Rb United States

Ryunosuke Machida Japan

P. J. Loehrer

125 ×0.4

NEURO

226 ×1.0

ONCOL

302 ×1.6

SURGE

68 ×0.5

EDM

69 ×0.5

EPIDE

Citations per year, relative to P. J. Loehrer P. J. Loehrer (= 1×) peers Ryunosuke Machida

Countries citing papers authored by P. J. Loehrer

Since Specialization

Citations

This map shows the geographic impact of P. J. Loehrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. J. Loehrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. J. Loehrer more than expected).

Fields of papers citing papers by P. J. Loehrer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. J. Loehrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. J. Loehrer. The network helps show where P. J. Loehrer may publish in the future.

Co-authorship network of co-authors of P. J. Loehrer

This figure shows the co-authorship network connecting the top 25 collaborators of P. J. Loehrer. A scholar is included among the top collaborators of P. J. Loehrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. J. Loehrer. P. J. Loehrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Shinozaki, Eiji, Stéphanie Laurent, Cristina Grávalos, et al.. (2015). 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). European Journal of Cancer. 51. S383–S384. 5 indexed citations

Shahda, Safi, Ming Yu, Joel Picus, et al.. (2011). Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102—Final report.. Journal of Clinical Oncology. 29(15_suppl). 3587–3587. 6 indexed citations

Anthony, Lowell, P. J. Loehrer, Siew Hong Leong, et al.. (2010). Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma.. Journal of Clinical Oncology. 28(15_suppl). TPS220–TPS220. 6 indexed citations

Anderson, Shannon W., Higinia R. Cárdenes, Fatih Akisik, et al.. (2010). Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC).. Journal of Clinical Oncology. 28(15_suppl). 4139–4139. 5 indexed citations

Cárdenes, Higinia R., Mark Powell, P. J. Loehrer, et al.. (2009). E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis. Journal of Clinical Oncology. 27(15_suppl). 4627–4627. 4 indexed citations

Wierzbicki, Rafal, Derek J. Jonker, Malcolm J. Moore, et al.. (2008). A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4065–4065. 5 indexed citations

Loehrer, P. J., et al.. (2008). A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. Journal of Clinical Oncology. 26(15_suppl). 8018–8018. 20 indexed citations

Lewis, David A., et al.. (2008). Imatinib for the treatment of thymic carcinoma. Journal of Clinical Oncology. 26(15_suppl). 8116–8116. 53 indexed citations

Loehrer, P. J.. (2008). Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. Yearbook of Medicine. 2008. 211–212. 3 indexed citations

10.

Burns, Matthew, et al.. (2008). A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. Journal of Clinical Oncology. 26(15_suppl). 19087–19087. 69 indexed citations

11.

Loehrer, P. J., Mark Powell, Higinia R. Cárdenes, et al.. (2008). A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. Journal of Clinical Oncology. 26(15_suppl). 4506–4506. 120 indexed citations

12.

Loehrer, P. J.. (2006). Risk of Fracture After Androgen Deprivation for Prostate Cancer. Yearbook of Medicine. 2006. 185–185. 8 indexed citations

13.

Kurup, Anupama, et al.. (2005). Phase II study of gefitinib treatment in advanced thymic malignancies. Journal of Clinical Oncology. 23(16_suppl). 7068–7068. 71 indexed citations

14.

Hanna, Nasser H., et al.. (2001). High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience. Bone Marrow Transplantation. 28(5). 435–438. 19 indexed citations

15.

Nichols, Craig R., Bruce J. Roth, P. J. Loehrer, Stephen D. Williams, & Lawrence H. Einhorn. (1994). Salvage chemotherapy for recurrent germ cell cancer.. PubMed. 21(5 Suppl 12). 102–8. 26 indexed citations

16.

Nichols, C R, et al.. (1993). Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols. JNCI Journal of the National Cancer Institute. 85(1). 36–40. 160 indexed citations

17.

Loehrer, P. J., et al.. (1992). Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Lung Cancer. 8(3-4). 240–240. 1 indexed citations

18.

Loehrer, P. J., et al.. (1985). Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.. PubMed. 69(12). 1359–63. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact